Research
Research

CASS4 Gene Guides Microglia to Sequester Alzheimer’s Plaques

By Dr. Elena Voss ·

Microglia, not Neurons, Are the Key Players

Neuroscientists at the University of Virginia School of Medicine have identified how the CASS4 gene, a major genetic risk factor for Alzheimer’s disease, operates in the brain. Published in the Journal of Experimental Medicine, the study shows that CASS4 directs microglial cells—brain immune cells—to capture and contain amyloid‑beta plaques, rather than acting within neurons as previously thought. The research was conducted by Dr. John Lukens and his team, who used mouse models and human brain tissue to trace the gene’s activity.

The team discovered that CASS4 is highly expressed in microglia, the brain’s resident immune cells. By using genetic knock‑out mice lacking CASS4, researchers observed a dramatic increase in plaque spread and neuronal damage. „When CASS4 is absent, microglia fail to form tight boundaries around plaques,” explained Dr. Lukens. The absence of these boundaries allows toxic amyloid‑beta to diffuse, accelerating neurodegeneration. The study also revealed that CASS4 activates a signaling pathway that promotes microglial adhesion and motility, enabling them to cluster around plaques efficiently.

How Does CASS4 Alter Microglial Behavior?

Detailed imaging showed that CASS4 interacts with integrin receptors on microglial surfaces. This interaction enhances the cells’ ability to adhere to extracellular matrix components surrounding plaques. Moreover, CASS4 upregulates the expression of scavenger receptors that bind amyloid‑beta, facilitating its internalization. The researchers measured a 60% reduction in plaque burden in mice with normal CASS4 activity compared to knock‑outs. Human post‑mortem samples mirrored these findings, with higher CASS4 levels correlating with tighter plaque encapsulation and less neuronal loss.

The discovery raises the possibility of boosting CASS4 function as a treatment strategy. „If we can pharmacologically enhance CASS4 signaling, we might improve microglial containment of plaques and slow disease progression,” suggested Dr. Lukens. Current Alzheimer therapies largely target amyloid‑beta directly; this approach would instead strengthen the brain’s natural defense mechanisms. However, translating these findings into drugs will require careful modulation, as overactivation of microglia could trigger inflammation.

Can Targeting CASS4 Offer a New Therapeutic Avenue?

What is the main function of CASS4 in Alzheimer’s disease? CASS4 directs microglia to adhere to and surround amyloid‑beta plaques, forming protective barriers that limit plaque spread and neuronal damage.

Frequently Asked Questions

How was the role of CASS4 discovered? Researchers used genetic knock‑out mice and human brain tissue, combined with imaging and molecular assays, to show that loss of CASS4 impairs microglial plaque containment.

Could enhancing CASS4 activity be a viable treatment? Potentially, yes. Strengthening CASS4 signaling might improve microglial function and plaque containment, but further studies are needed to assess safety and efficacy.